Online citations, reference lists, and bibliographies.
← Back to Search

Association Of Vasoactive Intestinal Peptide With Polymer-grafted Liposomes: Structural Aspects For Pulmonary Delivery.

B. Stark, P. Debbage, F. Andreae, W. Mosgoeller, R. Prassl
Published 2007 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
A polymer-grafted liposomal formulation that has the potential to be developed for aerosolic pulmonary delivery of vasoactive intestinal peptide (VIP), a potent vasodilatory neuropeptide, is described. As VIP is prone to rapid proteolytic degradation in the microenvironment of the lung a proper delivery system is required to increase the half-life and bioavailability of the peptide. Here we investigate structural parameters of unilamellar liposomes composed of palmitoyl-oleoyl-phosphatidylcholine, lyso-stearyl-phosphatidylglycerol and distearyl-phosphatidyl-ethanolamine covalently linked to polyethylene glycol 2000, and report on VIP-lipid interaction mechanisms. We found that the cationic VIP is efficiently entrapped by the negatively charged spherical liposomes and becomes converted to an amphipathic alpha-helix. By fluorescence spectroscopy using single Trp-modified VIP we could show that VIP is closely associated to the membrane. Our data suggest that the N-terminal random-coiled domain is embedded in the interfacial headgroup region of the phospholipid bilayer. By doing so, neither the bilayer thickness of the lipid membrane nor the mobility of the phospholipid acyl chains are affected as shown by small angle X-ray scattering and electron spin resonance spectroscopy. Finally, in an ex vivo lung arterial model system we found that liposomal-associated VIP is recognized by its receptors to induce vasodilatory effects with comparable high relaxation efficiency as free VIP but with a significantly retarded dilatation kinetics. In conclusion, we have designed and characterized a liposomal formulation that is qualified to entrap biologically active VIP and displays structural features to be considered for delivery of VIP to the lung.
This paper references
10.1016/0196-9781(87)90013-1
VIP receptors in mesenteric and coronary arteries: A radioligand binding study
M. Huang (1987)
10.1165/AJRCMB/2.5.449
Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi.
E. Tam (1990)
10.1002/JPS.1023
Trends and developments in liposome drug delivery systems.
T. Lian (2001)
10.1016/S0005-2736(03)00197-4
Lipid membranes with grafted polymers: physicochemical aspects.
D. Marsh (2003)
10.1172/JCI17500
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
V. Petkov (2003)
10.3109/10611869408996815
Sterically stabilized liposomes: physical and biological properties.
M. Woodle (1994)
10.1093/bioinformatics/18.1.211
DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra
A. Lobley (2002)
10.3181/00379727-203-43616
Peptidase Modulation of Airway Effects of Neuropeptides
C. Lilly (1993)
10.1124/pr.56.2.7
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
M. Delgado (2004)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1152/ajpregu.1998.275.1.R56
Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
H. Ikezaki (1998)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
Interaction of class A amphipathic helical peptides with phospholipid unilamellar vesicles.
J. A. Gazzara (1997)
10.1016/0005-2736(91)90201-I
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
10.1016/S0006-3495(92)81897-0
Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential.
M. Woodle (1992)
10.1074/jbc.M002325200
Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist
P. Nicole (2000)
10.1073/PNAS.88.24.11460
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
10.1016/S0167-7799(98)01220-7
Novel applications of liposomes.
D. Lasic (1998)
10.1093/bioinformatics/16.4.404
The PSIPRED protein structure prediction server
L. McGuffin (2000)
10.1016/S0196-9781(99)00161-8
Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin☆
I. Rubinstein (1999)
10.1016/0005-2736(90)90440-Y
Liposomes for the sustained drug release in vivo.
G. Blume (1990)
10.1152/AJPREGU.1997.273.1.R287
Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo.
F. Séjourné (1997)
10.1016/J.CHEMPHYSLIP.2005.02.003
Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer.
Olga Garbuzenko (2005)
The role of endogenous lung neuropeptides in regulation of the pulmonary circulation.
Keith Im (2000)
Phosphorus assay in column chromatography.
G. R. Bartlett (1959)
10.1002/BIP.360370504
Mechanisms for the modulation of membrane bilayer properties by amphipathic helical peptides
Richard M. Epand (1995)
10.1111/J.1399-3011.1997.TB00620.X
Conformational study of vasoactive intestinal peptide by computational methods.
M. Filizola (1997)
10.1093/nar/gkh371
DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data
L. Whitmore (2004)
10.1016/0024-3205(94)00425-0
Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.
X. Gao (1994)
10.1016/S0928-0987(01)00147-6
Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion.
R. Abu-Dahab (2001)
10.1016/S0006-3495(95)80369-3
Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol).
A. Kenworthy (1995)
10.1248/BPB1978.14.126
Enzymatic degradation of helodermin and vasoactive intestinal polypeptide.
M. Hachisu (1991)
Stabilization of vasoactive intestinal peptide by lipids.
G. Gololobov (1998)
10.1378/CHEST.124.3.1067
Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: analysis in neuronal nitric oxide synthase knockout mice.
N. Hasaneen (2003)
10.1016/S0006-3495(97)78066-4
Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes.
K. Edwards (1997)
10.1021/LA047588Y
Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media.
L. Arleth (2005)
10.1016/0005-2736(94)90183-X
Partitioning of vasoactive intestinal polypeptide into lipid bilayers.
Y. Noda (1994)
10.1007/978-1-4757-2508-7_3
Determination of Protein Secondary Structure
S. Venyaminov (1996)
10.1016/S0196-9781(03)00033-0
Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity
H. Önyüksel (2003)
10.1016/J.EJPHAR.2005.12.055
Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
D. Groneberg (2006)
10.1074/jbc.M513305200
Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor
Yossan-Var Tan (2006)
10.1093/nar/gki410
Protein structure prediction servers at University College London
K. Bryson (2005)
10.1046/J.1365-2125.2003.01893.X
Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.
N. Labiris (2003)
10.1021/BI00291A005
Amphipathic helix and its relationship to the interaction of calcitonin with phospholipids.
R. Epand (1983)
10.2174/1381612033391667
VIP and drug design.
I. Gozes (2003)
10.1016/S1359-0294(00)00090-X
Liposome application: problems and prospects
Y. Barenholz (2001)
10.1107/S0021889800008372
Solving the generalized indirect Fourier transformation (GIFT) by Boltzmann simplex simulated annealing (BSSA)
A. Bergmann (2000)
10.1006/JMBI.1999.3091
Protein secondary structure prediction based on position-specific scoring matrices.
D. Jones (1999)



This paper is referenced by
10.1016/B978-0-12-391860-4.00017-3
Nanoparticle-mediated treatment of pulmonary arterial hypertension.
W. Mosgoeller (2012)
10.2147/IJN.S63190
Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
Pritesh P. Jain (2014)
10.1016/j.ejps.2010.08.010
Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure.
B. Stark (2010)
Critical Reviews TM in Therapeutic Drug Carrier Systems EDITORIAL BOARD
A. Banga (2010)
10.1016/j.jconrel.2008.06.005
Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
K. Wernig (2008)
10.1016/j.jconrel.2015.05.287
Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.
B. Vaidya (2015)
10.1016/j.jconrel.2013.01.011
Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
V. Gupta (2013)
10.3109/10611860903508796
VPAC receptor mediated tumor cell targeting by protamine based nanoparticles
Anna Ortner (2010)
VPAC receptors as target for anti-cancer drug delivery
Raphaela E. Kaisler (2008)
10.4155/tde.13.71
Liposomal formulations for inhalation.
D. Cipolla (2013)
Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.
C. Rangger (2013)
10.1089/jamp.2008.0686
Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size.
Z. Li (2008)
10.3109/03639045.2012.693503
A study of the chemical and biological stability of vasoactive intestinal peptide
X. Cui (2013)
10.2147/IJN.S4937
Nanomedicine in pulmonary delivery
H. M. Mansour (2009)
10.3109/08982100903311812
Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals
A. Helbok (2010)
10.1016/j.pharmthera.2008.10.002
Therapeutic targets in pulmonary arterial hypertension.
C. Rhodes (2009)
10.1016/j.ejpb.2008.04.015
Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
B. Stark (2008)
10.1152/ajplung.00041.2008
Pulmonary applications and toxicity of engineered nanoparticles.
J. W. Card (2008)
10.1016/j.biotechadv.2015.01.010
Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers.
M. Witting (2015)
10.1016/j.nano.2011.04.012
Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.
A. Helbok (2012)
10.1016/j.ijpharm.2008.01.046
Inhalable liposomal formulation for vasoactive intestinal peptide.
Franz Hajos (2008)
10.1016/J.JCONREL.2007.05.026
Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
X. Gao (2007)
10.1517/17425247.2012.735658
Liposomal delivery of proteins and peptides
Janani Swaminathan (2012)
10.5772/28902
Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development
S. Sharma (2011)
Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.
A. Mathioudakis (2013)
10.3109/1061186X.2012.685477
Liposomes and their applications in molecular imaging
M. Silindir (2012)
10.1016/J.EJPB.2014.10.010
Pulmonary delivered polymeric micelles--pharmacokinetic evaluation and biodistribution studies.
X. Hu (2014)
10.1016/j.ejphar.2016.10.014
Conjugated Alpha-Alumina nanoparticle with vasoactive intestinal peptide as a Nano-drug in treatment of allergic asthma in mice.
S. Athari (2016)
Pharmaceutical Nanotechnology Inhalable liposomal formulation for vasoactive intestinal peptide
Franz Hajos (2008)
10.2147/IJN.S18739
Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques
G. Almer (2011)
10.1016/j.jconrel.2012.05.040
Recent advances in nanocarrier-based mucosal delivery of biomolecules.
Olga Kammona (2012)
10.2147/IJN.S66830
Interleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions
G. Almer (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar